Associations of plasma ergothioneine levels with cognitive function change in non-demented older Chinese adults: A community-based longitudinal study
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Aim
Animal studies have reported that ergothioneine (ET) exert a protective effect on cognitive function, but evidence from humans remains limited. In this study, we explored the association between plasma ET levels and cognitive change in a prospective cohort study specifically focused on older adults without dementia in Shanghai.
Methods
This analysis was based on 1,131 community-dwelling elder Chinese (mean age 69 years) from the Shanghai Brain Aging Study. Ultra-high-performance liquid chromatography-mass spectrometry was used to measure plasma ET at baseline. Cognitive function was assessed at baseline and follow-up (mean 2.0 years) via the Montreal Cognitive Assessment (MoCA) by trained clinicians. Multivariable linear regression evaluated ET-cognition associations with confounder adjustment.
Results
Each 1-SD increase in ET was associated with a 0.23 higher point in MoCA changes (95% CI: 0.04–0.43, P =0.021) after adjustment for age, sex, smoking, alcohol, diet score, educational level, BMI, hypertension, hyperlipidemia, diabetes, cardiovascular disease, APOE ε4 status and baseline MoCA scores. Sex-stratified analysis revealed a significant association in men ( β =0.78 per SD, 95% CI: 0.35–1.21, P < 0.001), but not in women ( P for interaction = 0.017). Dose-response curves indicated plateauing effects above 1000 ng/mL. Domain-specific analyses identified significant protective associations for visuospatial/executive function ( β =0.08, 95% CI: 0.02–0.14) and delayed recall ( β =0.11, 95% CI: 0.02–0.20).
Conclusions
Our findings indicate that higher plasma ET levels are significantly associated with slower cognitive decline independent of confounders in non-demented community-dwelling elderly participants, with such association observed in men but not women.
